The iConsensus consortium is a collaborative research project built onto a network of academic and industrial experts in different technologies. It couples together the co-creators of the new technologies and end-users from European academies and SME's as well as EFPIA partners. 

iConsensus is funded through the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking and is listed under grant agreement No. 777397. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI2 supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.


EFPIA companies
  • Bayer Aktiengesellschaft,  Germany
  • Glaxosmithkline Research And Development LTD., United Kingdom
  • Pfizer Limited, United Kingdom
  • Rentschler Biopharma Se, Germany
  • Sanofi-Aventis Deutschland GMBH, Germany
  • Synthon Biopharmaceuticals BV, Netherlands
  • UCB Biopharma SPRL, Belgium
  • Kungliga Tekniska Hoegskolan, Sweden
  • Rheinisch-Westfaelische Technische Hochschule Aachen, Germany
  • Universitaet Hohenheim, Germany
  • Universite De Mons, Belgium
Small and medium-sized enterprises (SMEs) 
  • Iprasense, France
  • Ipratech SA, Belgium
  • Kantisto BV, Netherlands
  • M2p-Labs GMBH, Germany
  • Micronit Microtechnologies BV, Netherlands
  • Paia Biotech GMBH, Germany
  • Presens Precision Sensing GMBH, Germany
  • Svanholm.Com Aps, Denmark